{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:03:16Z","timestamp":1784599396072,"version":"3.55.0"},"reference-count":30,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hipert.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T11:37:42Z","timestamp":1731843462000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recommendations for the management of patients with type 2 diabetes at hospital discharge after an ischaemic cardiovascular event"],"prefix":"10.20960","volume":"41","author":[{"given":"N.F.","family":"Renna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Zaidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2024.07.006_bib0150","unstructured":"INDEC, Argentina. 4.\u00aa Encuesta Nacional de Factores de Riesgo 2018 [accessed 1 Ago 2023] Available from: https:\/\/www.indec.gob.ar\/ftp\/cuadros\/publicaciones\/enfr_2018_resultados_definitivos.pdf"},{"key":"10.1016\/j.hipert.2024.07.006_bib0295","first-page":"398","article-title":"Resultados argentinos sobre prevalencia de enfermedad cardiovascular en diabetes mellitus tipo 2 [CAPTURE Study: Argentine results on prevalence of cardiovascular disease in type 2 diabetes mellitus]","volume":"82","author":"Dieuzeide","year":"2022","journal-title":"Medicina (B Aires)."},{"key":"10.1016\/j.hipert.2024.07.006_bib0160","doi-asserted-by":"crossref","first-page":"pA829","DOI":"10.1016\/j.jval.2015.09.307","article-title":"Resource Use and Costs of Congestive Heart Failure Hospitalizations: A Retrospective Cohort Study In Argentina","volume":"18","author":"Augustovski","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.hipert.2024.07.006_bib0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2021.1997288","article-title":"Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients","volume":"38","author":"Gracia-Ramos","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hipert.2024.07.006_bib0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(20)30381-8","article-title":"Management of diabetes and hyperglycaemia in the hospital","volume":"9","author":"Pasquel","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hipert.2024.07.006_bib0175","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: An Endocrine Society clinical practice guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hipert.2024.07.006_bib0180","first-page":"313","article-title":"Management of Hyperglycemia in Hospitalized Adults: Guidelines from the Endocrine Society","volume":"108","author":"Arnold","year":"2023","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.hipert.2024.07.006_bib0185","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1932296820932903","article-title":"Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic","volume":"14","author":"Galindo","year":"2020","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.hipert.2024.07.006_bib0190","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1177\/19322968231191104","article-title":"A Consensus Statement for Continuous Glucose Monitoring Metrics for Inpatient Clinical Trials","volume":"17","author":"Spanakis","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.hipert.2024.07.006_bib0300","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and Methodology: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care."},{"key":"10.1016\/j.hipert.2024.07.006_bib0205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9149(01)01720-9","article-title":"Body mass index and the risk of recurrent coronary events following acute myocardial infarction","volume":"88","author":"Rea","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hipert.2024.07.006_bib0210","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.neurol.2020.06.019","article-title":"Association of obesity with recurrent stroke and cardiovascular events","volume":"177","author":"Kumral","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.hipert.2024.07.006_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/DMSO.S153133","article-title":"Linking care of patients with obesity to outpatient weight control clinics following acute hospitalizations","volume":"11","author":"Harris","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.hipert.2024.07.006_bib0305","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.hipert.2024.07.006_bib0220","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.07.006_bib0225","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.07.006_bib0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies","volume":"12","author":"Caruso","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.hipert.2024.07.006_bib0235","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.07.006_bib0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.hipert.2024.07.006_bib0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2024.2322527","article-title":"BP-lowering effects of SGLT-2 inhibitors and finerenone: An indirect comparison in patients with chronic kidney disease and type 2 diabetes","volume":"25","author":"Georgianos","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.hipert.2024.07.006_bib0310","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis."},{"issue":"25.","key":"10.1016\/j.hipert.2024.07.006_bib0255","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2024.07.006_bib0260","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2024.07.006_bib0265","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.hipert.2024.07.006_bib0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2024.07.006_bib0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.hipert.2024.07.006_bib0280","doi-asserted-by":"crossref","unstructured":"Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76:1117-1145.","DOI":"10.1016\/j.jacc.2020.05.037"},{"key":"10.1016\/j.hipert.2024.07.006_bib0285","series-title":"Diabetes mellitus y ri\u00f1\u00f3n Enfoque transdisciplinario","author":"Elbert","year":"2022"},{"issue":"Suppl 1","key":"10.1016\/j.hipert.2024.07.006_bib0290","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1889-1837(24)00075-8","article-title":"Documento de consenso sobre tabaquismo y riesgo vascular","volume":"41","author":"Abell\u00e1n Alem\u00e1n","year":"2024","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.hipert.2024.07.006_bib0315","series-title":"Kaplan's Clinical Hypertension","author":"Kaplan","year":"2014"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:36Z","timestamp":1784596536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183724000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1889183724000904"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2024.07.006","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the management of patients with type 2 diabetes at hospital discharge after an ischaemic cardiovascular event","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Espa\u00f1a S.L.U. on behalf of Sociedad Espa\u00f1ola de Hipertensi\u00f3n - Liga Espa\u00f1ola para la Lucha contra la Hipertensi\u00f3n Arterial (SEH-LELHA), Sociedad Argentina de L\u00edpidos and Federacion Argentina de Cardiologia (FAC).","name":"copyright","label":"Copyright"}]}}